# BioOrbit

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bioorbit

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.bioorbit.space
- Total disclosed funding: $14M
- Latest round: Seed (Mar 2, 2026)
- Investors on record: 6

## About

BioOrbit, headquartered in London, UK, specializes in the innovative manufacture of biologic medications using advanced protein crystallization techniques developed for microgravity environments, enhancing drug delivery and patient care.BioOrbit, founded in 2023, is dedicated to producing pharmaceutical-grade crystals that improve the administration of biologic drugs. The company completed its first funding round in May 2026, raising GBP 9.8 million in Seed funding from investors including LocalGlobe and Breega. The founder's previous ventures are not specified, and there is no indication of mergers or subsidiaries.BioOrbit specializes in revolutionizing the administration of biologic medications by utilizing protein crystallization techniques developed for microgravity environments. The company’s core product is the production of pharmaceutical-grade crystals that enhance the stability and efficacy of biologic drugs, facilitating at-home injections for patients. This innovative approach addresses significant challenges in the healthcare sector, such as reducing the need for cold chain logistics and ensuring controlled release profiles for more effective treatment plans. The primary end users of BioOrbit's offerings include healthcare providers, pharmaceutical companies, and patients requiring biologic therapies, particularly in advanced markets like the United States and European Union, where the demand for enhanced drug delivery systems is growing rapidly. BioOrbit’s services are tailored to meet the needs of these diverse stakeholders, focusing on the critical intersection of biotechnology and patient care.BioOrbit operates on a revenue model that includes partnerships with pharmaceutical companies and direct sales of its innovative drug delivery solutions. The company engages in contract agreements with clients to collaborate on the development and production of biologic medications using their advanced crystallization technology, which encompasses bulk supply agreements for their flagship products. This B2B model allows for streamlined delivery and possibly subscription-style arrangements for ongoing supply, with pricing structures tailored to individual contracts based on the unique needs of each client.In May 2026, BioOrbit raised GBP 9.8 million in Seed funding co-led by new investors LocalGlobe and Breega, with participation from Seedcamp, AUXXO, Type One Ventures, and 7percent Ventures. The funding will support the development of space-based manufacturing capabilities for biologic medicines, enabling large-scale pharmaceutical production in orbit. BioOrbit plans to expand its market presence, focusing on the United States and European Union, where it will launch new products within the next few years.

## Funding rounds

- Seed, Mar 2, 2026, $14M — Seedcamp, Breega, 7percent Ventures, LocalGlobe, Type One Ventures, AUXXO

## Investors

- Seedcamp (https://capitalatlas.ai/funds/seedcamp) — Seed
- Breega (https://capitalatlas.ai/funds/breega) — Seed
- 7percent Ventures (https://capitalatlas.ai/funds/7percent-ventures) — Seed
- LocalGlobe (https://capitalatlas.ai/funds/localglobe) — Seed
- Type One Ventures (https://capitalatlas.ai/funds/type-one-ventures) — Seed
- AUXXO (https://capitalatlas.ai/funds/auxxo) — Seed